Who Counts as Vulnerable, and Why the Rules Differ

Part of Human Subjects Protection for Clinical Research Staff: Vulnerable Populations and Undue Influence.

About 5 minutes. Free, in your language, no account needed.

Why this matters

Some people are more likely to be pushed into a research decision, or less able to protect their own interests once in a study. The rules respond to that. At a site, you are often the first person the participant sees, so you need to know who the rules are worried about and why.

ICH E6(R3) is the international baseline in this course. The US federal regulations (HHS 45 CFR 46, FDA 21 CFR 50 and 56, HIPAA 45 CFR 164) are taught as the detailed worked example, and passages that name them are US law. Outside the United States, follow your national law and ethics committee requirements. State or local rules may add requirements. When this lesson says "the rules," that is the frame.

Two lists, not one

The Common Rule (45 CFR 46.111) tells the IRB to be particularly cognizant of research with categories of subjects who are vulnerable to coercion or undue influence. Its examples are children, prisoners, individuals with impaired decision-making capacity, and economically or educationally disadvantaged persons. When subjects are likely to be vulnerable, the IRB must see that additional safeguards are included in the study.

FDA's IRB rule (21 CFR 56.111) has its own list: children, prisoners, pregnant women, handicapped or mentally disabled persons, and economically or educationally disadvantaged persons.

Compare the two. Pregnant women appear in FDA's list but not in the Common Rule's list. Impaired decision-making capacity appears in the Common Rule's list, and FDA uses different wording. The lists are examples of an idea. A good habit is to ask of any participant, "Does something about this person's situation make it harder to say no, or harder to look after their own interests?"

What the IRB does about it

The IRB has to determine that selection of subjects is equitable (45 CFR 46.111(a)(3), 21 CFR 56.111(a)(3)). If an IRB regularly reviews research involving a vulnerable category, it should consider including one or more members who are knowledgeable about and experienced in working with those people (45 CFR 46.107(a), 21 CFR 56.107(a)).

ICH E6(R3) Principle 1.4 adds a second angle. Participant selection should be representative of the groups the product is intended to benefit, and the scientific goal should be considered so that particular populations are not unnecessarily excluded. Protection has two sides: do not exploit vulnerable people, and do not shut them out without good reason.

Capacity and comprehension

People with impaired decision-making capacity are one named category. If a participant cannot consent, ICH E6(R3) describes enrollment through the legally authorized representative (LAR), with the participant informed in a manner that facilitates understanding (sections 2.8.5 and 2.8.13). US rules say "LAR" and ICH says "legally acceptable representative." They are used for the same idea.

The regulations read for this course do not set a federal procedure for assessing capacity. The protocol and the IRB set it. At your site, follow the capacity steps in the approved protocol.

The Belmont Report makes a related point. Special provision may be needed when comprehension is severely limited, for example by immaturity or mental disability, and each class of subjects that might be considered incompetent should be considered on its own terms.

Where the law differs by place

The US regulations defer to other law in several places. "Children" are persons who have not reached the legal age for consent to the treatments or procedures involved, under the law where the research is conducted (45 CFR 46.402(a)). The definition of an LAR also depends on applicable law (46.102(i)). The Common Rule does not displace state, local or foreign laws that provide additional protections (46.101(f), (g)), and ICH E6(R3) is read with local regulatory requirements.

In practice

A coordinator at a dermatology site is screening for a study that may include adults who cannot consent for themselves. The approved protocol says how capacity is assessed and who may act as LAR. She does not decide on her own whether a participant "seems fine." She follows the protocol steps, and when a case is unclear she asks the investigator before anything else happens. She also asks the IRB office whether the participant's state has rules about representatives that change the plan.

What this looks like when it goes wrong

A site hears that a nearby clinic serves many people who are economically disadvantaged and starts approaching them first because they enroll fast and rarely ask questions. Nobody wrote this down or thought of it as selection. Weeks later a monitor notices that participants almost all come from one clinic. The site has a selection problem, and it has to explain to the IRB why people were approached the way they were.

Key takeaways